Barclays PLC Caladrius Biosciences, Inc. Transaction History

Barclays PLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	SELL	$0.83 - $1.22 $17,465 - $25,672	-21,043 Reduced 99.72%	60 $0
Q3 2021 Nov 09, 2021	BUY	$1.15 - $1.57 $17,117 - $23,369	14,885 Added 239.39%	21,103 $26,000
Q2 2021 Aug 13, 2021	BUY	$1.4 - $1.9 $8,621 - $11,700	6,158 Added 10263.33%	6,218 $10,000
Q4 2019 Feb 10, 2020	SELL	$2.02 - $2.85 $6 - $8	-3 Reduced 4.76%	60 $0
Q3 2019 Nov 14, 2019	BUY	$2.22 - $2.99 $6 - $8	3 Added 5.0%	63 $0
Q3 2018 Nov 14, 2018	SELL	$4.85 - $6.5 $2,910 - $3,900	-600 Reduced 90.91%	60 $0
Q2 2018 Aug 14, 2018	BUY	$3.8 - $8.64 $2,276 - $5,175	599 Added 981.97%	660 $4,000
Q1 2018 May 15, 2018	BUY	$3.7 - $6.09 $3 - $6	1 Added 1.67%	61 $0
Q3 2017 Nov 14, 2017	BUY	$3.58 - $4.34 $214 - $260	60	60 $0

Ticker CLBS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,583,200
Market Cap $25.8M
Description
Caladrius Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical li...

Get notified when there are updates to the investment portfolio of Barclays PLC, based on Form 13F filings with the SEC.

Stay updated on Barclays PLC with notifications on news.